These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31937617)

  • 1. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
    McCartney A; Bonechi M; De Luca F; Biagioni C; Curigliano G; Moretti E; Minisini AM; Bergqvist M; Benelli M; Migliaccio I; Galardi F; Risi E; De Santo I; Romagnoli D; Biganzoli L; Di Leo A; Malorni L
    Clin Cancer Res; 2020 May; 26(9):2131-2139. PubMed ID: 31937617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Bertolini I; Crucitta S; Fontanelli L; Rofi E; De Angelis C; Diodati L; Cavallero D; Gianfilippo G; Salvadori B; Fogli S; Falcone A; Scatena C; Naccarato AG; Roncella M; Ghilli M; Morganti R; Fontana A; Danesi R
    Breast Cancer Res Treat; 2019 Nov; 178(1):57-62. PubMed ID: 31346846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
    Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
    Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer.
    Yu Y; Sun W; Liu Y; Wang D
    J Clin Pharmacol; 2022 Mar; 62(3):376-384. PubMed ID: 34554584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
    Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
    Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
    Malorni L; Piazza S; Ciani Y; Guarducci C; Bonechi M; Biagioni C; Hart CD; Verardo R; Di Leo A; Migliaccio I
    Oncotarget; 2016 Sep; 7(42):68012-68022. PubMed ID: 27634906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
    Moftakhar B; Lekkala M; Strawderman M; Smith TC; Meacham P; Fitzgerald B; Falkson CI; Dhakal A
    Breast Cancer Res Treat; 2020 Sep; 183(2):411-418. PubMed ID: 32671612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
    Malorni L; Tyekucheva S; Hilbers FS; Ignatiadis M; Neven P; Colleoni M; Henry S; Ballestrero A; Bonetti A; Jerusalem G; Papadimitriou K; Bernardo A; Seles E; Duhoux FP; MacPherson IR; Thomson A; Davies DM; Bergqvist M; Migliaccio I; Gebhart G; Zoppoli G; Bliss JM; Benelli M; McCartney A; Kammler R; De Swert H; Ruepp B; Fumagalli D; Maibach R; Cameron D; Loi S; Piccart M; Regan MM; ;
    Eur J Cancer; 2022 Mar; 164():39-51. PubMed ID: 35172272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer.
    Talia M; Cirillo F; Scordamaglia D; Di Dio M; Zicarelli A; De Rosis S; Miglietta AM; Capalbo C; De Francesco EM; Belfiore A; Grande F; Rizzuti B; Occhiuzzi MA; Fortino G; Guzzo A; Greco G; Maggiolini M; Lappano R
    J Exp Clin Cancer Res; 2024 Jun; 43(1):171. PubMed ID: 38886784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
    Arnedos M; Bayar MA; Cheaib B; Scott V; Bouakka I; Valent A; Adam J; Leroux-Kozal V; Marty V; Rapinat A; Mazouni C; Sarfati B; Bieche I; Balleyguier C; Gentien D; Delaloge S; Lacroix-Triki M; Michiels S; Andre F
    Ann Oncol; 2018 Aug; 29(8):1755-1762. PubMed ID: 29893769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
    Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
    JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER
    Petroni G; Buqué A; Yamazaki T; Bloy N; Liberto MD; Chen-Kiang S; Formenti SC; Galluzzi L
    Clin Cancer Res; 2021 Apr; 27(7):1855-1863. PubMed ID: 33495311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.